Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase II Trial of Erlotinib and Bevacizumab in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations

NCT01562028 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.

NCT NCT01562028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01562028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase II Trial of Erlotinib and Bevacizumab in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations
Lead sponsor
ETOP IBCSG Partners Foundation
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2012
Completion date
October 31, 2018
Enrollment
109 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer